Tests, vaccines, and treatments would be provided through the regular health care system
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
WEDNESDAY, Aug. 17, 2022 (HealthDay News) -- The Biden administration plans to stop buying COVID-19 tests, vaccines, and treatments as early as the fall, White House COVID-19 Response Coordinator Ashish Jha, M.D., said Tuesday.
Under that plan, those products would be provided through the regular health care system, Jha said at an event sponsored by the U.S. Chamber of Commerce Foundation, CNN reported. While the government would still invest in next-generation vaccines and pandemic preparedness, commercialization on tests, vaccines, and treatments would begin this fall and expand in 2023, Jha noted. That transition will require working through regulatory issues, market dynamic issues, and equity issues, he explained.
"Right now, everybody can walk into a CVS and get a vaccine. I want to make sure that when we make this transition, we don't end up at a point where nobody can get a vaccine because we didn't get the transition right," he said.
A deal for $10 billion in additional COVID-19 funds did not pass Congress this year, so funding was shifted from increasing testing supplies and protective equipment in the national stockpile to buying updated vaccine boosters that offer some protection against new variants of the virus, such as the omicron subvariants BA.4 and BA.5, CNN reported. Those are expected in early to mid-September.
"Those vaccines are coming very, very soon. And so it's going to be really important that people this fall and winter get the new shot. It's designed for the virus that's out there," Jha said. "And again, based on everything we've seen so far, all the data suggests it should be highly effective against the new variants."
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on September 21, 2022
Read this Next
Other Trending Articles